Zydus Lifesciences shares jump 3% as USFDA inspection concludes at Ahmedabad plant

Zydus Lifesciences shares surged as much as 2.7% to touch an intraday high of ₹937.75 on Wednesday, May 6, as the pharma company said a USFDA inspection ended at its Ahmedabad plant.

“We wish to inform you that the USFDA conducted a GMP surveillance inspection for the company’s Unit 9 facility located at Zydus Biotech Park, Changodar, Ahmedabad. The inspection was conducted from 27th April to 5th May 2026,” the company said in a regulatory filing.

The inspection was closed with seven observations. Zydus further said that there were no data integrity-related observations. “The Company will closely work with the USFDA to address the observations expeditiously,” it added.

Zydus Lifesciences share price

At 12:20 PM, Zydus Lifesciences shares were trading at ₹936.20 apiece on the National Stock Exchange, gaining 2.63%.

In the last five days, shares of the firm have surged 4%, while for a month's time, they have advanced 8%. From the beginning of the year, Zydus Lifesciences shares have climbed 2%.

The company has a market capitalisation of ₹ 94,208.66 crore.

Shares of the company had touched their one-year high of ₹1,059.05 apiece on September 19, 2025, while their 52-week low of ₹835.50 was hit on April 2, 2026.

Zydus Lifesciences Q3 earnings

Zydus Lifesciences had reported a 29.6% jump in its net profit to ₹1,024 crore for the October-December quarter of the current fiscal (Q3 FY25), as compared to ₹790 crore posted in the year-ago period.

The company’s revenue from operations stood at ₹5,269 crore, up 17% as compared to ₹4,505 crore reported in Q3 FY24.

Its earnings before interest, taxes, depreciation and amortisation (EBITDA) stood at ₹1,388 crore for the reporting quarter, up 26% YoY as compared to ₹1,102 crore in Q3 FY24. EBITDA margin was 26.3% for Q3 FY25.

In the Indian business, the company had registered revenues of ₹1,947 crore in the December quarter, up 7% YoY. For the US formulations business, the registered revenues were at ₹2,410 crore in Q3 FY25, up 31% YoY.

Moreover, in the international markets, the formulations business' revenues stood at ₹570 crore, up 16% YoY.